H1A

H1A is a novel humanized monoclonal antibody targeting Programmed Death-Ligand 1 (PD-L1), currently in preclinical development for the treatment of renal cell carcinoma (RCC). Developed by researchers at the Mayo Clinic, H1A distinguishes itself from conventional PD-L1 inhibitors (such as atezolizumab) by inducing the degradation of the PD-L1 protein. This unique mechanism not only prevents the interaction between PD-L1 and its receptor PD-1 but also terminates pro-tumorigenic intracellular signaling pathways within the tumor cell. Preclinical studies have demonstrated that H1A treatment leads to the expansion of effector NK and CD8+ T cells while avoiding the enrichment of regulatory T cells (Tregs) often associated with other checkpoint inhibitors. In humanized mouse models and patient-derived ex-vivo assays, H1A has shown superior antitumor activity and tumor cell killing compared to FDA-approved agents like nivolumab, pembrolizumab, and atezolizumab.